FOXO4-DRI is an investigational, animal-stage senolytic peptide with no approved human dosing. This page provides no protocol. Any amounts that appear in animal papers are experimental model parameters, not medically established human doses. Any use should start low and be supervised by a qualified clinician.
Overview
FOXO4-DRI is a designed peptide studied in animals as a senolytic — an agent meant to clear senescent ("aged") cells. Because it has not been through human trials, there is no clinical dosing reference, only research parameters that do not translate to people.
Why there is no human dose
Unlike compounds with a commonly cited community range, FOXO4-DRI has no stable dosing pattern to report:
- Human dosing normally comes from clinical trials and pharmacokinetic studies — FOXO4-DRI has none.
- Amounts in animal studies are model-specific parameters that do not map onto human doses.
- Senolytics are often described as "hit-and-run" agents — given intermittently to clear senescent cells rather than continuously — but this is a research concept, not a validated schedule, and any circulating figures are unverified.
How it is administered
FOXO4-DRI is a research powder reconstituted with a sterile diluent for injection. Its D-retro-inverso design is intended to resist enzymatic breakdown and extend stability, which shapes how exposure would behave over time.
- Any amount depends on reconstitution — diluent volume sets concentration.
- As an unregulated compound, actual identity and purity are not verified.
Why oversight matters
FOXO4-DRI is not FDA-approved, has no monitoring standard, and clearing senescent cells is a powerful biological action with unknown human safety. Any concrete dosing decision would require clinical evidence that does not yet exist. This belongs within controlled research under expert supervision.